AstraZeneca’s Gout Drug Zurampic Clears FDA; Renal, CV Safety Trial Required
Label includes box warning on acute renal failure risk.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.